Uso de beta-bloqueadores en pacientes con enfermedad pulmonar obstructiva crónica

Use of beta-blockers in patients with COPD

Publicado 2013-03-25

Abrir | Descargar
PDF FLIP
Número
Vol. 25 Núm. 1 (2013)
Sección
Reportes de casos
Cómo citar
Uso de beta-bloqueadores en pacientes con enfermedad pulmonar obstructiva crónica.
rev. colomb. neumol. [Internet]. 2013 Mar. 25 [cited 2024 Nov. 21];25(1). Disponible en: https://doi.org/10.30789/rcneumologia.v25.n1.2013.130
DOI

https://doi.org/10.30789/rcneumologia.v25.n1.2013.130
Dimensions
PlumX
Licencia

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

José Alex Casallas Osorio, MD.
Universidad Nacional de Colombia. Bogotá, Colombia.
    Mostrar biografía de los autores

    José Alex Casallas Osorio, MD.,

    Residente Medicina Interna, Universidad Nacional de Colombia. Bogotá, Colombia.

    La enfermedad pulmonar obstructiva crónica (EPOC) es un síndrome sistémico con múltiples fenotipos, en el que la enfermedad cardiovascular contribuye significativamente a la morbilidad y la mortalidad por su causa. El tabaquismo, la clase socioeconómica baja y un estilo de vida sedentario contribuyen a la historia natural de cada una de estas condiciones. La mayoría de las enfermedades cardiovasculares requieren tratamiento con beta-bloqueadores, que tradicionalmente se han contraindicado en los pacientes con EPOC; sin embargo el uso de estos fármacos se asocia a beneficios y mejores resultados en pacientes con enfermedades cardiovasculares, hipertensión, insuficiencia cardiaca, enfermedad coronaria y enfermedad pulmonar obstructiva crónica.

    Visitas del artículo 2818 | Visitas PDF 1334

    Descargas

    Los datos de descarga todavía no están disponibles.
    1. Global Initiative for chronic obstructive lung disease GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2013. Disponible en: http://www.goldcopd.org.
    2. Minino AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. 2011; 59: 1-126. PubMed PMID: 22808755.
    3. Menezes AM, Pérez-Padilla R, Jardim JR, Muino A, López MV, Valdivia G, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005; 366 (9500): 1875-81.
    4. Caballero As, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, et al. Prevalence of COPD in Five Colombian Cities Situated at Low, Medium, and High Altitude (PREPOCOL Study)*. CHEST Journal. 2008; 133: 343-9.
    5. Ministerio de Salud y Protección Social. Tomo III-Morbilidad y mortalidad de la población colombiana. 2010. Disponible en: http://www.minsalud.gov.co/salud/Paginas/An%C3%A1lisis-dela-
    6. Situaci%C3%B3n-de-Salud-en-Colombia.aspx.
    7. Miravitlles M, Calle M, Soler-Cataluña JJ. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Archivos de Bronconeumología. 2012; 48: 86-98.
    8. Louie S, Zeki AA, Schivo M, Chan AL, Yoneda KY, Avdalovic M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert review of clinical pharmacology. 2013; 6: 197-219.
    9. Carolan BJ, Sutherland ER. Clinical phenotypes of chronic obstructive pulmonary disease and asthma: Recent advances. J Allerg Clin Immunol. 2013; 131: 627-34.
    10. Centers for Disease Control and Prevention (CDC). Smokingattributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004. MMWR Morbidity and mortality weekly report. 2008; 57: 1226-8.
    11. Man JP, Sin DD, Ignaszewski A, Man SF. The complex relationship between ischemic heart disease and COPD exacerbations. Chest. 2012; 141: 837-8.
    12. Patel ARC, Donaldson GC, Mackay AJ, Wedzicha JA, Hurst JR. The Impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD impact of ischemic heart disease on COPD. CHEST Journal. 2012; 141: 851-7.
    13. Chatterjee S. A 13-item score based on readily available risk factors predicted risk for 3-year mortality in heart failure. Ann Intern Med. 2013; 158 (2).
    14. Maclay JD, MacNee W. Cardiovascular disease in COPD: Mechanisms. CHEST Journal. 2013; 143: 798-807.
    15. Sin DD. Is COPD really a cardiovascular disease? CHEST Journal. 2009; 136: 329-30.
    16. Andrus MR, Loyed JV. Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues. Drugs & Aging. 2008; 25: 131-44.
    17. Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chronic Obstructive Pulmonary Disease. 2007; 2: 535-40.
    18. Mentz R, Wojdyla D, Fiuzat M, Chiswell K, Fonarow G, O’Connor C. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol. 2013; 111: 582-7.
    19. Nussbaumer-Ochsner Y, Rabe KF. Systemic Manifestations of COPD. CHEST Journal. 2011; 139: 165-73.
    20. Ertek S, Cicero A. Impact of physical activity on inflammation: effects on cardiovascular disease risk and other inflammatory conditions. Archives of medical science: AMS. 2012; 8: 794-804.
    21. Zvezdin B, Milutinov S, Kojicic M, Hadnadjev M, Hromis S, Markovic M, et al. A Postmortem analysis of major causes of early death in patients hospitalized with COPD Exacerbation. CHEST Journal. 2009; 136: 376-80.
    22. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012; 308: 1340-9.
    23. Angeloni E, Melina G, Roscitano A, Refice S, Capuano F, Lechiancole A, et al. β-Blockers improve survival of patients with chronic obstructive pulmonary disease after coronary artery bypass grafting. Ann Thorac Surg. 2013; 95: 525-31.
    24. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane database of systematic reviews (Online). 2005: CD003566.
    25. van Gestel YRBM, Hoeks SE, Sin DD, Welten GMJM, Schouten O, Witteveen HJ, et al. Impact of cardioselective β-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Resp Crit Care Med. 2008; 178: 695-700.
    26. Rutten Fh ZNAHEGDEHAW. Β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Int Med. 2010; 170: 880-7.
    27. Zeng Q, Jiang S. Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure. J Thorac Dis. 2012; 4: 310-5.
    28. Etminan M, Jafari S, Carleton B, FitzGerald J. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulmonary Medicine. 2012; 12: 48.
    29. Brunton L, Chabner B, Knollman B. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Twelfth Edition: McGraw-Hill Education; 2010.
    30. Laslett LJ, Alagona P, Jr., Clark BA, Drozda JP, Jr., Saldivar F, Wilson SR, et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol. 2012; 60: S1-49.
    31. Black HR, Greenberg BH, Weber MA. The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update. Am J Med. 2010; 123: S2.
    32. Saurav C, Giuseppe B-Z, Antonio A, Fabrizio DA, Davide C, Benjamin Van T, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013; 346.
    33. Poole-Wilson PA, Swedberg K, Cleland JGF, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. The Lancet. 2003; 362: 7-13.
    34. John W. Jenne MD. Beta blockers and COPD. Chest. 1980; 78: 675-6.
    35. Wunderlich J, Macha HN, Wudicke H, Huckauf H. Beta-adrenoceptor blockers and terbutaline in patients with chronic obstructive lung disease. Effects and interaction after oral administration. CHEST Journal. 1980; 78: 714-20.
    36. Ege M, Guray U, Guray Y, Yilmaz M, Yucel O, Zorlu A, et al. Acute heart failure with accompanying chronic obstructive pulmonary disease: should we focus on beta blockers? Herz. 2012; 37: 796-800.
    37. Short PM, Lipworth SIW, Elder DHJ, Schembri S, Lipworth BJ. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011; 342.
    38. Bryant L. β-blockers in COPD - yes, it’s OK (with care). J Primary Health Care. 2012; 4: 165.
    39. Suissa S, Ernst P. β-blockers for COPD inpatients. Thorax. 2012; 67: 936-7.
    40. Ni Y, Shi G, Wan H. Use of cardioselective β-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J Int Med Research. 2012; 40: 2051-65.
    41. Mainguy V, Girard D, Maltais F, Saey D, Milot J, Sénéchal M, et al. Effect of bisoprolol on respiratory function and exercise capacity in chronic obstructive pulmonary disease. Am J Cardiol. 2012; 110: 258-63.
    42. Stefan M, Rothberg M, Priya A, Pekow P, Au D, Lindenauer P. Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax. 2012; 67: 977-84.
    43. Stefan MS, Priya A, Rothberg M, Pekow PS, Lindenauer P. The effectiveness and safety of beta-blocker therapy for patients hospitalized for acute exacerbations of chronic obstructive lung disease with underlying comorbid ischemic heart disease or heart failure. Am J Respiratory Crit Care Med. 2012; 185 (1 Meeting Abstracts): A6638.
    44. Mentz R, Schulte P, Fleg J, Fiuzat M, Kraus W, Piña I, et al. Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: Findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION). Am Heart J. 2013; 165: 193-9.
    45. Ekström M, Bornefalk Hermansson A, Ström K. Effects of cardiovascular drugs on mortality in severe COPD: a time-dependent analysis. Am J Respiratory Crit Care Med. 2013;187: 715-20.
    46. Lainscak M, Gelbrich G, Inkrot S, Tahirovic E, Edelmann F, Doehner W, et al. Pulmonary function during beta-blocker titration in elderly patients with heart failure: The CIBIS-ELD Analysis. Am J Respiratory Crit Care Med. 2010; 181 (1 MeetingAbstracts): A6850.
    47. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010; 55: 1780-7.
    48. Herrin M, Feemster L, Crothers K, Uman J, Bryson C, Au D. Combination antihypertensive therapy among patients with COPD. Chest. 2013;143: 1312-20.

    Información

    Historia de la revista

    Palabras clave

    Código QR

    Patrocinadores

     Nos apoyan +Info Aquí 

     

    Directorios e indexadores

     

    Perfil de Google Scholar

    Más leídos en los últimos 30 días

    Número actual

    Sistema OJS 3.4.0.7 - Metabiblioteca |